Portretten voor de website van Crucell: corporate managementlid: Arthur Lahr
Arthur Lahr
Chief Executive Officer
Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he was consultant at McKinsey & Company and engineer at Unilever. At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch national plasma and blood product supplier. Mr. Lahr holds a Masters degree in Applied Physics from the University of Delft, The Netherlands, and an MBA from INSEAD, France.
RobbertvanHeekeren2
Robbert van Heekeren
Chief Financial Officer
Robbert van Heekeren is Chief Financial Officer of Kiadis Pharma. Before joining Kiadis Pharma he was Executive Director, Head Global Finance & Control at Organon, the former pharmaceutical business unit of AkzoNobel. Mr. Van Heekeren worked for Organon for more than 10 years in various international management positions. Mr. van Heekeren holds a Masters degree in Economics from Tilburg University, The Netherlands, and a Masters degree in Industrial Engineering & Management Science from Eindhoven University of Technology, The Netherlands.
Jan-Feijen
Jan Feijen
Chief Operations Officer
Jan Feijen is Chief Operating Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Vice President Manufacturing and Technical Operations, Platform Lead Vaccines and Advanced Therapies at Janssen (Pharmaceutical Companies of Johnson & Johnson). Prior to that he held various executive and project lead positions at Crucell, Avebe and Gist Brocades. Mr. Feijen holds a Masters degree in Technical Physics from the University of Delft, The Netherlands.
Jeroen_Rovers2
Jeroen Rovers MD PhD
Senior Vice President & Chief Medical Officer
Dr. Jeroen Rovers is Senior Vice President and Chief Medical Officer of Kiadis Pharma. He has more than 15 years of professional experience in clinical development, including conducting clinical trials, within academia and the pharmaceutical industry, among others as Chief Medical Officer at Ceronco Biosciences, VP Medical Affairs at Kiadis Pharma and Director of Clinical Development and Business Development at Organon. Dr. Rovers obtained his PhD at Leiden University, The Netherlands, on the use of light-activated drugs in the treatment of tumors.